LB Pharmaceuticals, Inc. LBRX 深 沪
等待开盘 04-01 09:30:00 美东时间
24.66
+1.410
+6.06%
华盛通- 最 高24.85
- 今 开23.58
- 成交量 31.30万股
- 最 低 22.51
- 昨 收 23.25
- 总市值 7.05亿
- 52周最高 27.55
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 13.36
- 委 比 99.00%
- 总股本 2860.57万
- 历史最高 27.55
- 量 比 1.93
- 振 幅 10.06%
- 历史最低 13.36
- 每 手 1
- 风险率 3.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
Stifel Maintains Buy on LB Pharmaceuticals, Raises Price Target to $40
Stifel analyst Paul Matteis maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the price target from $35 to $40.
03-27 21:47
LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 96.81 percent increase over losses of $(14.12) per share
03-27 04:30
LB Pharmaceuticals Starts Its Pivotal Phase 3 Study Of LB-102 To Treat Schizophrenia
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder
03-25 20:01
LB Pharmaceuticals Announces Up To $100M Private Offering of 4.72M Shares at $21.17 Each to Fund Clinical Trials
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases,
02-05 21:12
LB Pharmaceuticals Initiates Phase 2 Trial Evaluating Efficacy And Safety Of LB-102 In Patients With Bipolar Depression; Topline Data Expected In 1Q 2028
Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophreniaNEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX),
01-26 21:03
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
LB Pharmaceuticals appoints Ellen Rose as Senior Vice President, Corporate Affairs, and Lindsay Beaupre as Senior Vice President, People and Culture. Both bring extensive experience to support the company’s development of LB-102, a novel benzamide for schizophrenia and bipolar depression. LB-102 is advancing into pivotal Phase 3 trials for schizophrenia and Phase 2 for bipolar depression, with potential for additional indications.
01-06 12:00
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Stifel Maintains Buy on LB Pharmaceuticals, Raises Price Target to $35
Stifel analyst Paul Matteis maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the price target from $27 to $35.
2025-12-11 21:28
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals granted its new Chief Commercial Officer, Kaya Pai Panandiker, an equity award under the 2025 Equity Incentive Plan, including an option to purchase 195,000 shares at $21.36 per share, vesting over four years. The company’s lead product, LB-102, is a Phase 3-ready oral drug for schizophrenia and bipolar depression, with potential expansion into other neuropsychiatric conditions. LB Pharmaceuticals focuses on developing innovati...
2025-12-10 22:04
